Antiangiogenic agents after first line and sorafenib plus chemoembolization: a systematic review

Transarterial chemoembolization (TACE) is the standard treatment for intermediate stage, although the combination of TACE with sorafenib may theoretically benefit HCC patients in intermediate stage. Owing to the significant antiangiogenic effect of sorafenib and the limitation of TACE, it is rationa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Gardini, Andrea Casadei, Santini, Daniele, Aprile, Giuseppe, Silvestris, Nicola, Felli, Emanuele, Foschi, Francesco Giuseppe, Ercolani, Giorgio, Marisi, Giorgia, Valgiusti, Martina, Passardi, Alessandro, Puzzoni, Marco, Silletta, Marianna, Brunetti, Oronzo, Cardellino, Giovanni Gerardo, Frassineti, Giovanni Luca, Scartozzi, Mario
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2017
Assuntos:
Review
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5630448/
https://ncbi.nlm.nih.gov/pubmed/29029548
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.19449
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados